Amneal Pharmaceuticals, Inc.·4

May 8, 4:29 PM ET

BUCHI J KEVIN 4

Research Summary

AI-generated summary

Updated

Amneal (AMRX) Director Kevin Buchi Converts RSUs, Receives Award

What Happened

  • Director Buchi J. Kevin experienced the vesting/settlement of 34,819 restricted stock units (reported as a conversion/exercise of a derivative) on May 7, 2026 and, on May 6, 2026, was reported as acquiring a new award of 19,824 restricted stock units. The conversion shows 34,819 shares acquired and the same 34,819 shares disposed at $0 (derivative disposition), and the 19,824-unit award shows acquisition at $0. These transactions reflect awards/vesting and settlement activity rather than an open-market buy or sale.

Key Details

  • Transaction dates: May 6, 2026 (award of 19,824 RSUs); May 7, 2026 (conversion/settlement of 34,819 RSUs).
  • Prices/values reported: acquisitions at $0; the 34,819-share disposition reported at $0 (no cash proceeds shown).
  • Shares owned after transaction: not specified in the provided filing details.
  • Footnotes: F1—each restricted stock unit (RSU) is a contingent right to one share; F2—34,819 RSUs were originally granted May 6, 2025 and vested May 7, 2026; F3—vesting occurs per the grant’s schedule (first annual meeting or first anniversary rule).
  • Filing timeliness: Form 4 filed May 8, 2026 for May 6–7 transactions — appears to be filed within the usual 2-business-day window.

Context

  • These are derivative/RSU transactions: RSUs converted/settled into shares on vesting. The disposition reported at $0 commonly indicates shares were withheld or surrendered to cover tax withholding or similar employer-required withholdings (i.e., not an open-market sale). This type of insider filing documents compensation-related activity rather than a directional bet on the stock.